Search results for "Screening"

showing 10 items of 1150 documents

COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?

2020

The world is facing a new pandemic caused by a novel beta coronavirus (COVID 19), which causes severe respiratory coronavirus syndrome (SARS-CoV-2). Unfortunately, there are currently no US Food and Drug Administration (FDA) approved medications for the treatment of COVID-19 patients. High mortality rates in frail patients is a notable feature of the virus registered since the onset of COVID-19 pandemic. Above all, elderly patients or those with underlying chronic illnesses and compromised immune system are most at risk (1). Thus, the consideration is that the possible coexistence, in the same individual, of a cancer diagnosis and a COVID-19 infection could generate a synergistic negative p…

OncologyOpinionmedicine.medical_specialty2019-20 coronavirus outbreakCancer ResearchtherapyCoronavirus disease 2019 (COVID-19)business.industrySettore MED/06 - Oncologia MedicaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)screeningCancerCOVID-19medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282OncologyCOVID-19 cancer prognosis screening therapyInternal medicinemedicinecancerprognosisbusinessFrontiers in Oncology
researchProduct

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2…

2012

Abstract Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization. Methods: We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers. Results: There was strong evidence that the proportion of estrogen receptor (ER)-negative breast tumors decreased with age at diagnosis among BRCA1 (P-trend = 1.2 × 10−5), but increased with age at diagnosis among BRCA2, carriers (P-trend = 6.8 × 10−6). The proportion of triple-negative tumors decreased with age at diagnos…

OncologyPathologyendocrine system diseasesEpidemiologyGenes BRCA2Genes BRCA1Estrogen receptorGene mutation0302 clinical medicineCancer screeningMedicineskin and connective tissue diseasesEstrogen Receptor StatusOvarian Neoplasms0303 health sciencesMiddle Agedfemale genital diseases and pregnancy complications3. Good healthSerous fluidtriple-negative tumorsOncology030220 oncology & carcinogenesisFemaleestrogen receptorAdultmedicine.medical_specialtyBRCA1; BRCA2; breast cancer; estrogen receptor; triple-negative tumorsHereditary cancer and cancer-related syndromes Genetics and epigenetic pathways of disease [ONCOL 1]Breast NeoplasmsArticle03 medical and health sciencesbreast cancerBreast cancerSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Internal medicineHumansGenetic Predisposition to DiseaseGenetics and epigenetic pathways of disease Translational research [NCMLS 6]Germ-Line MutationAged030304 developmental biologyHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryCancerBRCA1medicine.diseaseBRCA2Neoplasm GradingbusinessOvarian cancer
researchProduct

Breath testing as a method for detecting lung cancer

2014

Early diagnosis of lung cancer is important due to high mortality in late stages of the disease. An ideal approach for population screening could be the breath analysis, due to its non-invasiveness, simplicity and cheapness. Using sensitive methods of analysis like gas chromatography/mass spectrometry in exhaled air of cancer patients were discovered some volatile organic compounds - possible candidates for cancer markers. However, these compounds were not specific for cancer cells. At the same time, integrative approaches used to analyze the exhaled breath have demonstrated high sensitivity and specificity of this method for lung cancer diagnosis. Such integrative approaches include detect…

Oncologyelectronic nosemedicine.medical_specialtyPathologyLung Neoplasms:MEDICINE [Research Subject Categories]Sensitivity and SpecificityGas Chromatography-Mass SpectrometryBreath testingInternal medicineCancer screeningBiomarkers TumormedicineHumansPharmacology (medical)Lung cancerEarly Detection of CancerNeoplasm StagingVolatile Organic CompoundsElectronic nosecancer diagnosticsbusiness.industryCancerExhalationexhaled breath analysismedicine.diseaselung cancerBreath TestsOncologyBreath gas analysisExhalationcancer screeningGas chromatographybusiness
researchProduct

Validation of monocyte distribution width decisional cutoff for sepsis detection in the acute setting

2021

not available

Oncologymedicine.medical_specialtyClinical BiochemistryMonocytesSepsisLeukocyte CountMDWSepsisInternal medicinemedicineHumansDistribution (pharmacology)Cutoffsepsis.business.industryscreeningMonocyteBiochemistry (medical)Reproducibility of ResultsHematologyGeneral Medicinemedicine.diseasemedicine.anatomical_structurebiomarkerBiomarker (medicine)businessBiomarkersCBCInternational Journal of Laboratory Hematology
researchProduct

Diagnosis of hepatocellular carcinoma (HCC) is better if early in any case.

2011

Oncologymedicine.medical_specialtyHepatocellular carcinoma Screening Liver cirrhosisbusiness.industryHepatocellular carcinomaInternal medicineInternal Medicinemedicinemedicine.diseasebusiness
researchProduct

Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

2018

Oncologymedicine.medical_specialtyMolecular screeningbusiness.industryAdvanced breastCancerHematologymedicine.diseaseBreast cancerOncologyInternal medicinemedicineAGATAbusinessAnnals of Oncology
researchProduct

Endometrial and Cervical Cancers

2021

Uterine corpus and cervical cancers are showing, in the last decades, increasing incidence and mortality in industrialized and developing countries, respectively; on the other hand, innovative therapeutic strategies are emerging for the management of advanced gynecological malignancies. Risk factors and predisposing conditions are widely and continually studied; thus, prevention, through lifestyle correction and/or validated screening tests, could represent a promising tool to diagnose earlier and reduce mortality of uterine cancers. Herein, management of endometrial and cervical tumors from diagnosis to commonly applied standards of care and experimental frontiers are depicted so as to pro…

Oncologymedicine.medical_specialtyScreening testbusiness.industryIncidence (epidemiology)Endometriummedicine.diseasemedicine.anatomical_structureUterine corpusUterine cancerInternal medicinemedicinePersonalized medicinebusinessCervixChemoradiotherapy
researchProduct

Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study

2012

Item does not contain fulltext INTRODUCTION: A recent genome-wide association study in European systemic sclerosis (SSc) patients identified three loci (PSORS1C1, TNIP1 and RHOB) as novel genetic risk factors for the disease. The aim of this study was to replicate the previously mentioned findings in a large multicentre independent SSc cohort of Caucasian ancestry. METHODS: 4389 SSc patients and 7611 healthy controls from different European countries and the USA were included in the study. Six single nucleotide polymorphisms (SNP): rs342070, rs13021401 (RHOB), rs2233287, rs4958881, rs3792783 (TNIP1) and rs3130573 (PSORS1C1) were analysed. Overall significance was calculated by pooled analys…

Oncologymedicine.medical_specialtysystemic sclerosisRHOBImmunologyGenome-wide association studySingle-nucleotide polymorphismBioinformaticsPolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyArticleWhite PeopleRheumatologyRisk FactorsInternal medicineRhoB GTP-Binding Proteinsystemic sclerosis; genome wide screening; genetic risk factorsmedicinegenetic risk factorsImmunology and AllergySNPHumansGenetic Predisposition to DiseaseAllelerhoB GTP-Binding ProteinRheumatology and AutoimmunityScleroderma Systemicbusiness.industryHaplotypeProteinsgenome wide screeningDNA-Binding ProteinsEuropeHaplotypesCohortEvaluation of complex medical interventions Auto-immunity transplantation and immunotherapy [NCEBP 2]businessGenome-Wide Association Study
researchProduct

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

2006

Item does not contain fulltext BACKGROUND: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether TP53 mutations classified as functionally inactive (< or=20% of wildtype transactivation ability) had different prognostic and predictive values in CRC compared with mutations that retained significant activity. MATERIALS AND METHODS: TP53 mutations within a large, international database of CRC (n = 3583) were classified ac…

Oncologyp53MaleNutrition and Diseasebinding domainsLymphovascular invasionColorectal cancerDNA Mutational AnalysisAetiology screening and detection [ONCOL 5]Gene mutationmedicine.disease_causeTransactivationVoeding en ZiekteAntineoplastic Combined Chemotherapy ProtocolsDeterminants in Health and Disease [EBP 1]transcriptional activityMutationHematologyExonsMiddle AgedSurvival RateOncologyAdenocarcinomaFemaleColorectal Neoplasmsmedicine.medical_specialtyAdenocarcinomachemotherapy colorectal cancer mutation prognosis TP53 transactivational abilityMolecular epidemiology [NCEBP 1]Breast cancerTranslational research [ONCOL 3]Interventional oncology [UMCN 1.5]Internal medicinemedicineHumansNeoplasm InvasivenessSurvival rateneoplasmsbreast-cancerVLAGAgedNeoplasm StagingHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryInternational Agenciesmedicine.diseaseImmunologyMutationTumor Suppressor Protein p53businessFollow-Up Studies
researchProduct

Breast Cancer Diagnosis in Coronavirus-Era: Alert From Italy

2020

OpinionCancer Research2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industrydiagnosisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)screeningCOVID-19medicine.diseasemedicine.disease_causelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensVirologylcsh:RC254-282Breast cancerbreast cancerOncologyItalymedicinebusinessCoronavirusFrontiers in Oncology
researchProduct